Other
Second-Line Treatment
0
Pipeline Programs↗
14
Active Trials↗
4
Companies Involved↗
Second-line Treatment is an early-stage landscape with 0 programs across 4 companies. The most active players are Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Integrated Community Oncology Network.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
40
clinical trials
Unknown status16 · 40%
Recruiting11 · 28%
Completed5 · 13%
Withdrawn3 · 8%
Not yet recruiting3 · 8%
Terminated2 · 5%
Clinical Trials
Trial Activity
40 trials
Clinical Study of OR for Second-line Treatment of Refractory MZL
Recruiting·—·Phase 4·NCT06134284·39 enrolled
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Recruiting·—·Phase 2·NCT06394674·84 enrolled
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
Recruiting·—·Phase 2·NCT06702826·20 enrolled
Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06876844·24 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)